Curia, formerly AMRI, a contract research, development and manufacturing organization, unveiled its messenger RNA (mRNA) ofering, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle (LNP) formulation and development for full-scale sterile fill-finish services.
 
The mRNA service is designed to streamline the development and delivery of mRNA-based products, which span various therapeutic areas including cancer, heart disease and chronic illnesses in addition to its current application in vaccines.
 
“The extraordinary impact of mRNA on the COVID-19 pandemic demonstrates its potential to save and improve lives,” said Curia Chairman and Chief Executive Officer John Ratliff. “mRNA has the potential to play a pivotal role in the next frontier of treatments for unmet medical needs. Curia’s capabilities enable customers to accelerate the discovery and development of next-generation mRNA therapeutics from curiosity to cure.”